Prosecution Insights
Last updated: November 15, 2026
Application No. 17/375,735

APPARATUS, SYSTEMS AND METHODS FOR DETERMINING TISSUE OXYGENATION

Non-Final OA §103§DOUBLEPATENT
Filed
Jul 14, 2021
Priority
Mar 19, 2013 — provisional 61/803,451 +3 more
Examiner
LIU, CHU CHUAN
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Surgisense Corporation
OA Round
5 (Non-Final)
71%
Grant Probability
Favorable
5-6
OA Rounds
86%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
568 granted / 795 resolved
+1.4% vs TC avg
Moderate +15% lift
Without
With
+14.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
35 currently pending
Career history
833
Total Applications
across all art units

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s amendments and remarks filed on 08/28/2025 have been fully considered. Claims 1, 31-37, 39-44, and 46-51 are pending for examination. Claims 2-30, 38 and 45 are cancelled. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 31-32, 34-37, 39-43, 46, and 49-50 are rejected under 35 U.S.C. 103 as being unpatentable over Zand et al. (USPGPUB 2009/0234248 – cited in previous action), in view of Wilson et al. (USPGPUB 2009/0216097 – applicant cited) and further in view of Langan et al. (USPGPUB 2004/0106891). In regard to claims 1, 31, 42, and 49-50, Zand discloses a surgical instrument/ stapler anvil (Figs. 1-14 and associated descriptions; [0055]) configured to sense an injectable light re-emitting probe to resolve tissue oxygenation (tissue oxygenation and injected fluorescein dye/ fluorescent medium/ dye/ Ruthenium, [0016]; [0056]; [0066]; [0081]), the surgical instrument/ stapler anvil comprising: at least one optical emitter that is configured to excite the injectable light re-emitting probe within an absorption band of the injectable light re-emitting probe (light source(s) for fluorescent medium/ dye/ Ruthenium, [0056] and [0081]); at least one optical detector configured to receive re-emitted light from the injectable light re-emitting probe (light receivers, [0056] and [0081]); a temperature sensor that is configured to detect a temperature of the target tissue (sensor for temperature, [0082]); and a signal processor that is configured to resolve the tissue oxygenation based on the received re-emitted light (element 131, Figs. 1 and 3 and associated descriptions; tissue oxygenation using fluorescence based techniques/ time resolved methods, [0056]; [0081]), wherein the signal processor is configured to resolve the tissue oxygenation of at least one point of the target tissue by analyzing the received re-emitted light using time domain techniques (tissue oxygen content/ oxygen quantities…using time resolved methods, [0056] and [0081]), and wherein the instrument is further configured to detect at least one of blood oxygenation, pulse rate, pulse presence, pulse rhythm, tissue perfusion, oxygen delivery, oxygen utilization, tissue characterization, tissue general health, tissue flow dynamics, tissue immunologic activity, tissue pathogen concentration, tissue neoplastic cell content, or tissue dysplastic cell content ([0016] and [0056]). Zand does not specifically disclose the signal processor is configured to calibrate the tissue oxygenation by using the temperature detected by the temperature sensor. Wilson teaches an oxygen sensor probe for internal monitoring tissue oxygen (abstract; Figs. 1-3 and associated descriptions) comprises at least one optical emitter that is configured to excite an injectable light re-emitting probe and at least one optical detector configured to receive re-emitted light from the injectable light re-emitting probe (Figs. 1-3 and associated descriptions) and a processor ([0072]) configured to calibrate tissue oxygenation by using the temperature detected at measurement site (Figs. 1-3 and associated descriptions; Stern-Volmer relationship, [0032]; [0050]; calibration, [0058-0059]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the surgical instrument/ surgical stapler anvil (Zand) to incorporate the temperature calibration functions as taught by Wilson, since both systems are optical tissue oxygenation measuring devices and one of ordinary skill in the art would have recognized that temperature readings at the measurement side can be utilized to calibrate detected oxygen information (see Wilson). The rationale would have been to obtain more accurate tissue oxygenation information. Zand as modified by Wilson does not specifically disclose an applicator that is configured to contain or be coupled to a vessel containing a medium comprising the injectable light re-emitting probe, wherein the applicator comprises one or more needles that is configured to inject the medium into the target tissue. Langan teaches a localizing needle with fluid delivery (Figs. 1-3 and 15-17 and associated descriptions) comprises an applicator (elements 10, 12, 14, and/or 18, Fig. 1 and associated descriptions) that is configured to contain or be coupled to a vessel (coupled to syringe 28, Figs. 1 and 17 and associated descriptions) containing a medium comprising the injectable dye (Fig. 17 and associated descriptions; dye, [0069]), wherein the applicator comprises one or more needles that is configured to inject the medium into the target tissue (element 18, Figs. 1-3 and 15-17 and associated descriptions; target tissue, Fig. 17 and associated descriptions). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the surgical instrument/ surgical stapler anvil (Zand) to incorporate the configuration(s) of the syringe and needle and associated elements/function as taught by Langan, since one of ordinary skill in the art would have recognized that the configuration(s) as taught by facilitate injecting dye to a specific/ selected tissue site of the patient (see Langan). The rationale would have been to injecting the light re-emitting probe into/ near the target tissue site. In regard to claim 32, Zand as modified by Wilson and Langan discloses the signal processor is configured to resolve the tissue oxygenation based on a lifetime of the received re-emitted light ([0056]; [0066]; [0081] of Zand). In regard to claim 34, Zand as modified by Wilson discloses the applicator is at least one injector that is configured to inject the medium into the target tissue (injection, [0016]; [0056] of Zand; element 18, Figs. 1-3 and 15-17 and associated descriptions; target tissue, Fig. 17 and associated descriptions of Langan). In regard to claim 35, Zand as modified by Wilson and Langan discloses comprising an interrogator instrument that is configured to interrogate the target tissue (Fig. 13 and associated descriptions; [0079] of Zand). In regard to claim 36, Zand as modified by Wilson and Langan discloses the surgical instrument is a flexible substrate having a tissue interfacing surface (elements 1313 and 1311, Fig. 13 and associated descriptions; [0079] of Zand). In regard to claim 37, Zand as modified by Wilson and Langan discloses the signal processor makes a determination of an operation success based on a resolution of the tissue oxygenation (Fig. 14 and associated descriptions; [0080] of Zand). In regard to claim 39, Zand as modified by Wilson and Langan discloses at least one sensor configured to monitor interaction forces of at least one of compression pressure and tissue tension of the tissue (compression pressure, and tension on tissues, [0066]; pressure sensor 509, Fig. 5 and associated descriptions; [0071]; compression force, [0071-0073]; Claim 9 of Zand). In regard to claim 40, Zand as modified by Wilson and Langan discloses the injectable light re-emitting probe is a phosphorescent probe that has multiple absorption wavelengths (Ruthenium, [0056]; [0081] of Zand). In regard to claim 41, Zand as modified by Wilson and Langan discloses the surgical instrument is communicatively coupled to a base station (base station, [0021]; [0055]; claim 12 of Zand). In regard to claim 43, Zand as modified by Wilson and Langan discloses the surgical stapler anvil is communicatively coupled to a base station (base station, [0021]; [0055]; claim 12 of Zand). In regard to claim 44, Zand as modified by Wilson and Langan discloses wherein the signal processor makes a determination of an operation success based on the resolution of the tissue oxygenation (Fig. 14 and associated descriptions; [0080] of Zand). In regard to claim 46, Zand as modified by Wilson and Langan discloses at least one sensor configured to monitor interaction forces of at least one of compression pressure and tissue tension of the tissue (compression pressure, and tension on tissues, [0066]; pressure sensor 509, Fig. 5 and associated descriptions; [0071]; compression force, [0071-0073]; Claim 9 of Zand). Claim 33 is rejected under 35 U.S.C. 103 as being unpatentable over the combination of Zand, Wilson and Langan as applied to claims 1, 31-32, 34-37, 39-43, 46, and 49-50 above, and further in view of Sonnenschein et al. (USPGPUB 2003/0163029 – cited in previous action). In regard to claim 33, Zand as modified by Wilson and Langan discloses the surgical instrument comprises a stapler anvil ([0055] of Zand) but does not specifically disclose the surgical instrument is an endoscopic instrument. Sonnenschein teaches an endoscope instrument comprises a stapler anvil containing optical components (Fig. 10 and associated descriptions; [0086-0090]; [0104]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the surgical instrument (Zand as modified by Wilson) to be integrated in an endoscopic instrument as taught by Sonnenschein, since one of ordinary skill in the art would have recognized that endoscopic instruments facilitate internal optical/ imaging measurements of tissue. The rationale would have been to obtain tissue information in addition to endoscopic functions. Claims 47-78 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Zand, Wilson and Langan as applied to claims 1, 31-32, 34-37, 39-43, and 46 above, and further in view of Carp et al. (USPGPUB 2008/0004531 – cited in previous action). In regard to claims 47-48, Zand as modified by Wilson and Langan discloses to measure tissue oxygenation (tissue oxygenation using fluorescence based techniques/ time resolved methods, [0056]; [0081] of Zand) and interaction forces of at least one of compression pressure and tissue tension of the tissue (compression pressure, and tension on tissues, [0066]; pressure sensor 509, Fig. 5 and associated descriptions; [0071]; compression force, [0071-0073]; Claim 9 of Zand) but does not specifically disclose the signal processor is further configured to resolve the tissue oxygenation in a gated manner to at least one of an interaction force or a physiological parameter. Carp teaches to time resolve tissue oxygenation in a gated manner to at least one of an interaction force (Fig. 4 and associated descriptions; [0083]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the surgical instrument/ stapler anvil (Zand as modified by Wilson) to incorporate the function of resolve the tissue oxygenation in a gated manner to at least one of an interaction force as taught by Carp, since both devices are optical tissue oxygenation measurement systems and one of ordinary skill in the art would have recognized that tissue oxygenation varies with tissue compression force/ pressure (see Carp). The rationale would have been to obtain more information regarding tissue compression, blood flow and tissue oxygenation. Claim 51 is rejected under 35 U.S.C. 103 as being unpatentable over Zand in view of Wilson and further in view of Sonnenschein. In regard to claim 51, Zand discloses a surgical instrument/ stapler anvil (Figs. 1-14 and associated descriptions; [0055]) configured to sense an injectable light re-emitting probe to resolve tissue oxygenation (tissue oxygenation and injected fluorescein dye/ fluorescent medium/ dye/ Ruthenium, [0016]; [0056]; [0066]; [0081]), the surgical instrument/ stapler anvil comprising: at least one optical emitter that is configured to excite the injectable light re-emitting probe within an absorption band of the injectable light re-emitting probe (light source(s) for fluorescent medium/ dye/ Ruthenium, [0056] and [0081]); at least one optical detector configured to receive re-emitted light from the injectable light re-emitting probe (light receivers, [0056] and [0081]); a temperature sensor that is configured to detect a temperature of the target tissue (sensor for temperature, [0082]); and a signal processor that is configured to resolve the tissue oxygenation based on the received re-emitted light (element 131, Figs. 1 and 3 and associated descriptions; tissue oxygenation using fluorescence based techniques/ time resolved methods, [0056]; [0081]), wherein the signal processor is configured to resolve the tissue oxygenation of multiple points of the target tissue by analyzing the received re-emitted light using time domain techniques (tissue oxygen content/ oxygen quantities…using time resolved methods, [0056] and [0081]). Zand does not specifically disclose the signal processor is configured to calibrate the tissue oxygenation by using the temperature detected by the temperature sensor. Wilson teaches an oxygen sensor probe for internal monitoring tissue oxygen (abstract; Figs. 1-3 and associated descriptions) comprises at least one optical emitter that is configured to excite an injectable light re-emitting probe and at least one optical detector configured to receive re-emitted light from the injectable light re-emitting probe (Figs. 1-3 and associated descriptions) and a processor ([0072]) configured to calibrate tissue oxygenation by using the temperature detected at measurement site (Figs. 1-3 and associated descriptions; Stern-Volmer relationship, [0032]; [0050]; calibration, [0058-0059]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the surgical instrument/ surgical stapler anvil (Zand) to incorporate the temperature calibration functions as taught by Wilson, since both systems are optical tissue oxygenation measuring devices and one of ordinary skill in the art would have recognized that temperature readings at the measurement side can be utilized to calibrate detected oxygen information (see Wilson). The rationale would have been to obtain more accurate tissue oxygenation information. Zand as modified by Wilson discloses the surgical instrument comprises a stapler anvil ([0055] of Zand) but does not specifically disclose the surgical instrument is an endoscopic instrument. Sonnenschein teaches an endoscope instrument comprises a stapler anvil containing optical components (Fig. 10 and associated descriptions; [0086-0090]; [0104]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the surgical instrument (Zand as modified by Wilson) to be integrated in an endoscopic instrument as taught by Sonnenschein, since one of ordinary skill in the art would have recognized that endoscopic instruments facilitate internal optical/ imaging measurements of tissue. The rationale would have been to obtain tissue information in addition to endoscopic functions. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 31-37, 39-44, and 46-48 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-2 and 6-16 of U.S. Patent No. 9,420,967. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-2 and 6-16 of ‘967 anticipate claims 1, 31-37, 39-44, and 46-48 of present application. Response to Arguments Applicant’s amendment and argument with respect to claims 1 and 42 filed on 08/28/2025 have been fully considered but they are deemed to be moot in views of the new grounds of rejection. Applicant's arguments filed on 08/28/2025 have been fully considered but they are not persuasive. In regard to claim 51, applicant alleged that “it would not have been obvious to modify the endoscope of Sonnenschein to include the features of the endoscopic instruments as recited and there would not have been a reasonable expectation of success”. In response, the rejection was made by “modify the surgical instrument (Zand as modified by Wilson) to be integrated in an endoscopic instrument as taught by Sonnenschein” and the combined endoscope instrument facilitates obtaining tissue information in addition to endoscopic functions (see above). Examples of the combination/ integration of the endoscopic system and surgical stapler can be found in at least USPNs 5,131,379; 5,197,649; and 7,338,505. It is noted that the claim recites transitional phrase “comprising” which is inclusive or open-ended and does not exclude additional, unrecited elements or method steps (see MPEP 2111.03). The recited endoscopic instrument does not exclude an integrated surgical instrument/ stapler anvil and associated elements to perform the recited features/ functions. It is noted that the preamble of claim 51 merely recites “an endoscopic instrument” and the body of the claim recites the elements comprised in the endoscopic instrument. It is interpreted that the elements are comprised in any part(s)/ location(s) associated with the endoscopic instrument. In regard to the double patenting rejection, applicant requests the rejection be held, see page 9 of the Remarks filed on 08/28/2025. Thus, the rejection is maintained for the reasons of record. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHU CHUAN LIU whose telephone number is (571)270-5507. The examiner can normally be reached M-Th (6am-6pm). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Robertson can be reached at (571) 272-5001. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHU CHUAN LIU/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Show 8 earlier events
Aug 28, 2025
Response Filed
Sep 19, 2025
Final Rejection mailed — §103, §DOUBLEPATENT
Mar 19, 2026
Response after Non-Final Action
Mar 19, 2026
Notice of Allowance
Apr 13, 2026
Response after Non-Final Action
Oct 19, 2026
Request for Continued Examination
Oct 28, 2026
Response after Non-Final Action
Nov 06, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788359
PERSONAL SMART STETHOSCOPE AND AUSCULTATION METHOD USING COMPLEX BIO-SIGNAL SENSOR
2y 4m to grant Granted Nov 10, 2026
Patent 12778463
Method and Apparatus for Analyte Measurement Including Real-Time Quality Assessment and Improvement
3y 11m to grant Granted Nov 03, 2026
Patent 12773141
NON-INVASIVE BLOOD ANALYSIS USING A COMPACT CAPILLAROSCOPE AND MACHINE LEARNING TECHNIQUES
3y 4m to grant Granted Oct 27, 2026
Patent 12773137
SENSOR UNIT FOR MEASURING BIOMETRIC INFORMATION
2y 10m to grant Granted Oct 27, 2026
Patent 12773138
ORTHOGONALLY REDUNDANT SENSOR SYSTEMS AND METHODS
2y 7m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
71%
Grant Probability
86%
With Interview (+14.7%)
High
PTA Risk
Based on 795 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month